6185 — Cansino Biologics Share News
0.000.00%
Last trade - 00:00- HK$5.73bn
- HK$4.18bn
- CNY1.06bn
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025
Brief: CanSino Biologics Gets Clinical Trial Approval From NMPA To Initiate Clinical Trial For PCV24
Brief: CanSino Biologics Q3 Net Profit Up 842.0% Y/Y
Brief: CanSino Biologics Posts H1 Gross Profit of RMB296.6 MLN
Brief: CanSino Biologics H1 Net Loss 13.5 Million Yuan
CanSino jumps as China approves clinical trials for its new vaccine
Brief: Cansino Biologics Says Recombinant Poliomyelitis Vaccine Gets Clinical Trial Approval In China
Brief: Cansino Biologics Says NMPA Granted New Drug Application Approval To 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Brief: Cansino Biologics Says Inhaled TB Booster Obtains Clinical Trial Approval In Indonesia
Brief: Cansino Biologics Posts QTRLY Operating Revenue Of RMB137.2 Million
Brief: SPIMACO and CanSinoBIO Sign Agreement To Localise, Market MCV4 Vaccine In Saudi And MENA
Brief: CanSino Biologics's 2024 Net Loss At 378.9 Million Yuan
Brief: CanSino Biologics' Prelim 2024 Net Loss At 378.9 Million Yuan
Brief: CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China
CanSino jumps as NMPA grants priority review status to infant vaccine application
Brief: Cansino Biologics Says NMPA Grants Priority Review Status To NDA For DTcP Infant